Rapid Clinical Policy development: COVID-19

During the COVID-19 pandemic there has been a need to expeditiously develop clinical policies, both for commissioned specialized services as well as for the NHS more broadly.

We have developed a process to produce rapid clinical policies during the pandemic, a process that is a highly compressed version of the standard process used outside of emergencies. A rapid clinical policy statement is the end result of the expedited process, a document that defines access to a treatment for a particular group of patients during the COVID-19 pandemic or provides clinical policy guidance more broadly. All such rapidly developed policies and statements are interim for the COVID-19 period and will reviewed when the pandemic is over, with options thereafter including withdrawal, entering the full NHS policy development process, or entering the NICE Technology Appraisal Guideline process with appropriate follow-through action.

Primary care

Title Date published/updated
Interim Position Statement: Inhaled budesonide for adults (50 years and over) with COVID-19 13 April 2021
Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19 14 April 2020

 

Secondary care

Title Date published/updated
Interim Clinical Commissioning Policy: Thrombopoietin receptor agonists as first line therapy for new or relapsed immune thrombocytopenia in adults and children over the age of 1 year during the COVID-19 pandemic 19 April 2021
Interim Clinical Commissioning Policy: Tocilizumab for critically ill patients with COVID-19 pneumonia (adults) 22 February 2021
Interim Clinical Commissioning Policy: Sarilumab for critically ill patients with COVID-19 pneumonia (adults) 22 February 2021
COVID-19 therapy: corticosteroids including dexamethasone and hydrocortisone 13 November 2020
Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older) 15 June 2021
Ruxolitinib for chronic graft versus host disease 18 March 2021
Ruxolitinib for acute graft versus host disease 18 March 2021
Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at-risk pre-term infants 1 July 2020
Visiting healthcare inpatient settings during the COVID-19 pandemic 16 March 2020
Tocilizumab for giant cell arteritis (GCA) during the COVID-19 pandemic (RPS 2007) 18 March 2021
Eltrombopag as bridging therapy to haematopoietic stem cell transplant in severe or very severe aplastic anaemia during the COVID19 pandemic (in adults) 18 March 2021
Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19 14 April 2020

 

Community based health, social care, mental health trusts and ambulance services

Title Date published/updated
Interim Position Statement: Inhaled budesonide for adults (50 years and over) with COVID-19 13 April 2021
Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) in people with or at risk of COVID-19 14 April 2020